Appointment of a new Director to the Board of Directors of Immune Biosolutions Inc.

We are thrilled to welcome a new director to the board of directors of Immune Biosolutions Inc: Mr. Nicholas Franco. The arrival of Mr. Franco is part of the company’s development strategy. With over 32 years of experience in the pharmaceutical industry, research, marketing, sales, and business development in several therapeutic areas, both domestically and internationally, “He will certainly bring a unique strategic perspective of the industry and a vision focused on value creation to the Board,” says Luc Paquet, CEO of the company.

NewsGuest UserMay 1, 2023BIOOQuébecImmune Biosolutions, Board of directors

adMare BioInnovations Achieves Prestigious LEED Green Building Certification

adMare BioInnovations is pleased to announce it has achieved LEED® v4 certification for the conception and construction of Building 2 at the Montreal Innovation Centre. LEED (Leadership in Energy and Environmental Design) was developed by the U.S. Green Building Council (USGBC) and is administered in Canada by the Canada Green Building Council (CAGBC). LEED is the most widely used green building rating system in the world and an international symbol of excellence. Through design, construction, and operation practices that improve environmental and human health, LEED-certified buildings are helping to make the world more sustainable.

NewsGuest UserMay 1, 2023BIOOQuébecadMare BioInnovations, LEED, certification

CQDM, Feldan Therapeutics and Amgen fund development of innovative drug delivery technology to target lung diseases

CQDM is proud to announce the funding of a project worth $503,779 aiming at optimizing a new drug delivery platform in the lungs to treat several disabling pathologies such as chronic pulmonary obstruction and cystic fibrosis. CQDM is providing a grant of $201,512, made possible by the Ministère de l’Économie et de l’Innovation et de l’Énergie (MEIE). This funding, combined with the support of the Quebec company Feldan Therapeutics and the biotech company Amgen, will support the development of new therapeutic options. This project is part of a larger collaboration between the two companies, worth $1,427,757, to expand the potential of Feldan’s unique drug delivery technology.

NewsGuest UserApril 20, 2023BIOOQuébecCQDM, Feldan Therapeutics, Amgen, Drug delivery, lung diseases

Ontario Investing in New Innovative Hub to Grow the Life Sciences Sector in Kitchener and Waterloo

The Ontario government is investing $7.5 million to help build a state-of-the-art Innovation Arena at the University of Waterloo. The new $35 million facility will be a hub for innovation in Ontario’s life sciences sector in Kitchener and Waterloo, supporting the development of new health technology and the commercialization of intellectual property and encouraging investment and job creation.

NewsGuest UserApril 20, 2023BIOOQuébecbiomanufacturing, Innovation Arena, Life Science Ontario

New strategy positions B.C. as a global hub for life sciences

A new made-in-B.C. Life Sciences and Biomanufacturing Strategy outlines how the Province will capitalize on the industry value chain from discovery through to clinical trials and manufacturing by supporting targeted investments in people and infrastructure. To help grow innovative local companies, the Province is investing $10 million in a new wet lab facility with adMare Bioinnovations.

NewsGuest UserApril 20, 2023BIOOQuébecadMare BioInnovations, British Columbia, biomanufacturing

2023 Sweet Biopharma Day Winner is Epitopea!

Laval, Canada – (BUSINESSWIRE) – April 13, 2023 – BIOQuébec, CQDM, Fonds de solidarité FTQ and adMare BioInnovations, co-organizers of Sweet Biopharma Day, are pleased to announce that Epitopea, represented by Steven Klein, is the winner of the 2023 edition.

NewsGuest UserApril 17, 2023BIOOQuébecBIOQuébec

adMare BioInnovations launches the BioInnovation Scientist (BIS) Program: Foundations and invites early-career science professionals to apply to be part of the inaugural cohort

The adMare Academy is proud to launch the BioInnovation Scientist (BIS) Program: Foundations. This online, cohort-based program will provide early-career scientists with fundamental knowledge in therapeutics development while simultaneously building their professional skills to succeed in the Canadian life sciences industry.

Introducing Our New Life Sciences Division: Analytical Services for Vaccines and Biological Products

As a leading full-service analytical laboratory serving the pharmaceutical industry for more than 30 years, at Neopharm, we are investing in the development of a new facility with state-of-the-art technology to support the growing field of biological products in the healthcare industry.

EVAH Closes Series B Financing of $8.5 million

EVAH Corp. (EVAH or the company) has announced the successful completion of a Series B financing round, raising $8.5 million. This additional financing brings EVAH’s total funding since its launch in 2020 to $28.5 million.

A business and development platform in the animal health industry, EVAH specializes in the development of vaccines to prevent bacterial diseases in food animals. The company also designs microbiome solutions for improved growth performance and medicated feed against parasites.

NewsGuest UserMarch 29, 2023BIOOQuébecEVAH, animal health, vaccine production

Government of Canada improves access to affordable and effective drugs for rare diseases

In Canada, one out of twelve people—many of whom are children—has a rare disease. Unfortunately, treatments are only available for a small percentage of these conditions. Even when treatments that might dramatically improve the quality of a patient's life are available, they are often unaffordable and out of reach.

Today, the Honourable Jean-Yves Duclos, Minister of Health, announced measures in support of the first-ever National Strategy for Drugs for Rare Diseases, with an investment of up to $1.5 billion over three years. Through this, we will help increase access to, and affordability of, effective drugs for rare diseases to improve the health of patients across Canada, including children.

The Government of Canada continues to invest in domestic vaccine production

The Government of Canada continues to make significant investments to strengthen Canada’s biomanufacturing and life sciences sector. Our approach prioritizes innovative solutions and long-term domestic biomanufacturing capacity right here at home. Since March 2020, over $1.8 billion has been invested across 34 projects to rebuild Canada’s vaccines, therapeutics and biomanufacturing capacity.

NewsGuest UserMarch 29, 2023BIOOQuébecvaccine production, biomanufacturing

Clinical research to the power of 10

Diex Research announces the official opening of its Quebec City site since its relocation on September 12, 2022, which is now located at Place de la Cité. Diex Research is a leader in the clinical research industry and is committed to providing superior services to its clients while maintaining the highest standards for safety and ethics.

NewsGuest UserMarch 29, 2023BIOOQuébecDIEX Recherche, clinical research, innovation

Defence Therapeutics and Orano agree to collaborate on radio-immuno-conjugates

Under the agreement, Defence will develop the first radio-immuno-conjugate therapy based on an Auger electron emitter by combining Defence’s intracellular targeting and radiochemistry expertise provided by Orano SA, a world-renowned multinational company based in Chatillon, France.

AstraZeneca Announces Major Investment In Ontario Life Sciences Sector

AstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific and high-tech jobs to the Greater Toronto Area (GTA) in a major expansion of its research footprint in Canada. The investment will contribute to AstraZeneca’s Research & Development Hub (R&D) in Mississauga, which focuses on leading global clinical studies in areas including breast, lung and prostate cancer, COVID-19, and chronic kidney disease. It also includes the creation of a new Alexion, AstraZeneca Rare Disease Development Hub, which focuses on rare disease research.

Government of Canada establishes new research hubs to accelerate Canada’s vaccine and therapeutics production

Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, announced an investment of $10 million in support of the creation of five research hubs to accelerate Canada’s vaccine and therapeutics production.

Congruence Therapeutics Announces Close of Series A Extension, Bringing Total Round to Over US$65 Million

Congruence Therapeutics, announced today the close of an extension to its Series A financing, bringing the total amount raised to over US$65 million. This extension was led by new investor BDC Capital's Thrive Venture Fund, with participation from current investors Amplitude Ventures, Fonds de solidarité FTQ, OrbiMed, Investissement Quebec (IQ), SilverArc, and others.

NewsGuest UserMarch 16, 2023BIOOQuébecCongruence Therpeutics Inc., biotechnology, drug discovery

Emmanuelle Toussaint no longer holds the position of Executive Director at BIOQuébec.

We would like to notify you that as of February 17, 2023, Emmanuelle Toussaint no longer holds the position of Executive Director at BIOQuébec. BIOQuébec is very appreciative of the tremendous work done by Emmanuelle and grateful for her dedication and involvement over the past six months. We wish her continued success in her professional journey.

NewsGuest UserFebruary 22, 2023BIOOQuébecBIOQuébec

New BioAccelerator home to Canadian Alliance for Skills and Training in Life Sciences (CASTL) Expanded Training Facility

The Governments of Canada and Prince Edward Island today announced funding for a $50 million BioAccelerator, which will be home to CASTL’s (Canadian Alliance for Skills and Training in Life Sciences) headquarters and expanded training facility.

Aplantex Announces the Composition of Its C-Suite

Aplantex is pleased to announce the composition of the company’s C-suite. "Aplantex is the result of the innovative work of a multidisciplinary team of skilled individuals committed to simplifying and broadening access to the valuable plant-based bioactive molecules that daily impact our health and well-being," states Mr. Charest.

NewsGuest UserFebruary 14, 2023BIOOQuébecAplantex, bioactive molecules, plant-based, innovation, green biotechnology, biomass

adMare National Accelerator with Regional Partners Tx Accelerator

adMare invites Canada’s most promising and innovative early-stage life sciences therapeutics ventures to join its national Accelerator program which includes a partnership with MaRS in Ontario.